The blood–brain barrier (BBB) excludes the vast majority of cancer therapeutics from
normal brain. However, the importance of the BBB in limiting drug delivery and efficacy is …

Background: Sensitizing effects of poly-ADP-ribose polymerase inhibitors have been studied
in several preclinical models, but a clear understanding of predictive biomarkers is lacking. …

Prognosis of patients with glioblastoma (GBM) remains dismal despite maximal surgical
resection followed by aggressive chemo-radiation therapy. Almost every GBM, regardless of …

Purpose: Effective sensitizing strategies potentially can extend the benefit of temozolomide (TMZ)
therapy in patients with glioblastoma (GBM). We previously demonstrated that robust …

Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide
efficacy in multiple tumor types; however, talazoparib-mediated sensitization has not …

The treatment of metastatic lesions in the brain represents a serious unmet medical need in
the field of neuro-oncology. Even though many effective compounds have demonstrated …

Purpose Histological diagnosis of glioblastoma (GBM) was determined by the presence of
necrosis or microvascular proliferation (histGBM). The 2021 WHO classification now …

Isocitrate dehydrogenase (IDH) 1 or 2 mutations confer a favorable prognosis compared to
IDH-wildtype in astrocytoma, frequently denoting a lower grade malignancy. However, recent …

High-grade gliomas are primary brain tumors that are incredibly refractory long-term to
surgery and chemoradiation, with no proven durable salvage therapies for patients that have …

Importance Nearly 96% of patients with high-grade glioma (HGG) report moderate-to-severe
fatigue. Armodafinil is a psychostimulant that might help cancer-related fatigue in patients …